About the Study Drug

Tasocitinib (CP-690,550) is being developed as a potential disease-modifying anti-rheumatic drug delivered orally in pill form.

Am I a Trial Candidate?

If you suffer from RA, you may be eligible to participate in the ORAL trials.

Call 800-718-1021.

Tell a Friend

Do you know someone with RA? Patients are being recruited now for the ORAL trials.

©2009 Pfizer, Inc. All rights reserved. JRS00038A.